154 related articles for article (PubMed ID: 24716637)
1. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
3. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.
Abu-Mouch S; Fireman Z; Jarchovsky J; Zeina AR; Assy N
World J Gastroenterol; 2011 Dec; 17(47):5184-90. PubMed ID: 22215943
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
7. Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kudo M; Kim KI; Taniguchi M; Imoto S; Mita K; Hayashi Y; Shoji I; El-Shamy A; Hotta H
Intervirology; 2010; 53(1):49-54. PubMed ID: 20068341
[TBL] [Abstract][Full Text] [Related]
8. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
9. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
10. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
Atsukawa M; Tsubota A; Shimada N; Kondo C; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Narahara Y; Osada Y; Yamaguchi H; Nakatsuka K; Iwakiri K; Kawamoto C; Sakamoto C
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):781-7. PubMed ID: 24732752
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
Guo X; Zhao Z; Xie J; Cai Q; Zhang X; Peng L; Gao Z
Virol J; 2012 Jun; 9():123. PubMed ID: 22713131
[TBL] [Abstract][Full Text] [Related]
13. IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
El Raziky M; Elsharkawy A; Said SE; Abdelatty S; El Akel W; Tantawy O; Gamal Eldeen H; Mabrouk M
J Interferon Cytokine Res; 2015 Aug; 35(8):649-53. PubMed ID: 25973761
[TBL] [Abstract][Full Text] [Related]
14. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C
J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.
Nimer A; Mouch A
World J Gastroenterol; 2012 Feb; 18(8):800-5. PubMed ID: 22371640
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.
Kim HB; Myung SK; Lee YJ; Park BJ;
J Hum Nutr Diet; 2018 Apr; 31(2):168-177. PubMed ID: 28833855
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Yee BE; Nguyen NH; Zhang B; Vutien P; Wong CR; Lutchman GA; Nguyen MH
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1189-201. PubMed ID: 25171028
[TBL] [Abstract][Full Text] [Related]
19. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.
Akuta N; Suzuki F; Fukushima T; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Clin Microbiol; 2013 Sep; 51(9):2862-8. PubMed ID: 23784126
[TBL] [Abstract][Full Text] [Related]
20. Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
Iwane S; Mizuta T; Kawaguchi Y; Takahashi H; Oza N; Oeda S; Nakashita S; Kuwashiro T; Otsuka T; Kawazoe S; Eguchi Y; Anzai K; Ozaki I; Fujimoto K
Intern Med; 2015; 54(24):3113-9. PubMed ID: 26666596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
